Relationship Between RAR and MACEs in AMI-CS Patients During Hospitalization

NCT07507110 | Completed DMC

• 1 other identifier: XZXY-LJ-20210715-056
• Study Type: observational
• Target: 264
• Locations: 1 country
• Sites: 1

Brief Summary

This is a retrospective study from double center: Xuzhou Central Hospital and The First People's Hospital of Yancheng. Acute myocardial infarction (AMI) were screened and AMI complicating with cardiogenic shock were included. This study is to investigate the relationship between red blood cell distribution width-to-albumin ratio (RAR) and major adverse cardiovascular events (MACEs) in acute myocardial infarction complicated with cardiogenic shock (AMI-CS) patients during hospitalization.

Conditions

Red Blood Cell Distribution Width-to-albumin Ratio; Acute Myocardial Infarction (AMI); Major Adverse Cardiovascular Events

Outcome Measures

Primary Outcomes (1)

• the occurrence of major adverse cardiovascular events (MACEs) during hospitalization.

  Include all-cause death, recurrent non-fatal myocardial infarction, unplanned revascularization, and non-fatal stroke.

  up to 1 month

Secondary Outcomes (1)

• individual components of MACEs

  up to 1 month

Study Arms (1)

AMI-CS

Diagnostic Test: Includ the inclusion/exclusion criteria of AMI-CS

Interventions

Includ the inclusion/exclusion criteria of AMI-CS DIAGNOSTIC_TEST

he inclusion criteria were as follows: (1) Age over 18 years and under 90 years; (2) Meeting the diagnostic criteria for acute myocardial infarction\[16\]: myocardial injury markers (preferably troponin) ≥ 99th percentile of the upper limit of normal value, combined with at least one evidence of myocardial ischemia: persistent myocardial ischemic symptoms ≥ 30 minutes; accompanied by ST-segment elevation or depression on electrocardiogram; (3) Meeting the diagnostic criteria for cardiogenic shock\[17\]: systolic blood pressure \< 90 mmHg, accompanied by clinical symptoms of pulmonary congestion such as dyspnea, and at least one of the following peripheral organ perfusion impairments: altered mental status; cold and clammy skin; urine output \< 30 ml/h; or serum lactate level \> 2.0 mmol/L. The exclusion criteria included: (1) Coexisting cerebrovascular disease, peripheral vascular disease or embolic disease; (2) Myocardial infarction caused by coronary artery embolism or blood flow interrupti

AMI-CS

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This is a retrospective study from double center: Xuzhou Central Hospital and The First People's Hospital of Yancheng. Between January 2019 and December 2024, a total of 3316 patients diagnosed with AMI were screened. Among them, 264 cases complicating with cardiogenic shock were included.

You may qualify if:

• Age over 18 years and under 90 years;
• Meeting the diagnostic criteria for acute myocardial infarction: myocardial injury markers (preferably troponin) ≥ 99th percentile of the upper limit of normal value, combined with at least one evidence of myocardial ischemia: persistent myocardial ischemic symptoms ≥ 30 minutes; accompanied by ST-segment elevation or depression on electrocardiogram;
• Meeting the diagnostic criteria for cardiogenic shock: systolic blood pressure \< 90 mmHg, accompanied by clinical symptoms of pulmonary congestion such as dyspnea, and at least one of the following peripheral organ perfusion impairments: altered mental status; cold and clammy skin; urine output \< 30 ml/h; or serum lactate level \> 2.0 mmol/L.

You may not qualify if:

• Coexisting cerebrovascular disease, peripheral vascular disease or embolic disease;
• Myocardial infarction caused by coronary artery embolism or blood flow interruption due to peripheral embolus detachment or invasive diagnostic and therapeutic procedures;
• History of surgery, trauma or infection within one month;
• History of severe liver or kidney dysfunction, , including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and γ-glutamyl transpeptidase (γ-GGT) \> 2.5 times upper limit of normal value; Serum creatinine \> 1.5 times upper limit of normal value;
• Coexisting autoimmune diseases, tumors, etc.

Sponsors & Collaborators

• Xuzhou Central Hospital: lead

Study Sites (1)

Xuzhou Central Hospital

Xuzhou, China

Location

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: March 24, 2026
• First Posted: April 2, 2026
• Study Start: July 1, 2019
• Primary Completion: October 31, 2024
• Study Completion: December 31, 2025
• Last Updated: April 2, 2026

Record last verified: 2026-03

Locations

CN (1)